Title of article
Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)
Author/Authors
Kim A. Papp، نويسنده , , Richard G Langley، نويسنده , , Mark Lebwohl، نويسنده , , Gerald G Krueger، نويسنده , , Philippe Szapary، نويسنده , , Newman Yeilding، نويسنده , , Cynthia Guzzo، نويسنده , , Ming-Chun Hsu، نويسنده , , Yuhua Wang، نويسنده , , Shu Li، نويسنده , , Lisa T Dooley، نويسنده , , Kristian Reich، نويسنده ,
Issue Information
روزنامه با شماره پیاپی سال 2008
Pages
10
From page
1675
To page
1684
Abstract
Background
Ustekinumab, a human monoclonal antibody against interleukins 12 and 23, has shown therapeutic potential for psoriasis. This study assessed the efficacy and safety of ustekinumab in psoriasis patients and assessed dosing intensification in part
Journal title
The Lancet
Serial Year
2008
Journal title
The Lancet
Record number
592891
Link To Document